Expertise in
7
conditions

Marc G. Berger

Clermont-ferrand, FR 
Expertise in
7
conditions
Clermont-ferrand, FR 

Overview

Marc Berger practices practicing medicine in Clermont-ferrand, France.

Mr. Berger is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Gaucher Disease Type 1, Chronic Myelogenous Leukemia (CML), Gaucher Disease, Splenomegaly, and Splenectomy.

He is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Clermont-ferrand, France
Other Locations
Lyon, France
Saint-etienne-de-valoux, France
Bordeaux, France
Pierre-la-treiche, 69495, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib
Study Phase: Phase 2
The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Enrollment Status: Completed
Publish Date: September 24, 2019
Intervention Type: Biological
Study Phase: Not Applicable
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: A Pilot Diagnostic Accuracy Study
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: A Pilot Diagnostic Accuracy Study
Enrollment Status: Completed
Publish Date: September 25, 2018
Intervention Type: Diagnostic test
View 3 Less Clinical Trials

88 Total Publications

Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation.
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation.
Journal: Journal of internal medicine
Published: February 28, 2026

Frequently Asked Questions about Marc G. Berger

Is Marc G. Berger a top-rated expert for Gaucher Disease Type 1?

MediFind is an objective health platform that identifies experts based on real-world data. Marc G. Berger is classified as an Elite expert for Gaucher Disease Type 1, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marc G. Berger participate in research or clinical trials?

Yes. Marc G. Berger has published 88 articles and abstracts on conditions like Gaucher Disease Type 1. You can view a list of Marc G. Berger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berger's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile